Merck MRK

HealthcareMarket cap $290B11 connections

Merck makes Keytruda - the world's best-selling cancer drug at $25B+ annually - which uses the immune system to attack tumors and is approved for 40+ cancer types. Its vaccines (Gardasil for HPV, Pneumovax) protect billions. Its Acceleron (pulmonary arterial hypertension) and Prometheus acquisitions expand beyond Keytruda. Post-Keytruda patent cliff strategy is Merck's defining challenge.

Explore Merck on the interactive map Relationship timeline Find a path to another company

Suppliers 7

Companies that sell to Merck

Thermo FisherHealthcare · $220BAnalytical instruments for R&D
IQVIAHealthcare · $45BReal-world evidence analytics
CencoraHealthcare · $45BDrug supply chain
Veeva SystemsTechnology · $32BVeeva platform for Merck global drug launches
West PharmaceuticalHealthcare · $15BWest packaging for Merck biologic drugs
BrukerHealthcare · $12BMerck uses Bruker mass spectrometers in R&D
DoximityHealthcare · $8BMerck physician marketing on Doximity

Partners 3

Strategic partnerships, joint products and alliances

IQVIAHealthcare · $45BReal-world evidence studies
ArvinasHealthcare · $3BBayer partnered with Arvinas on prostate cancer PROTAC
Recursion PharmaHealthcare · $2BMerck collaborates on Recursion AI drug programs

Competitors 2

Companies it competes with

AstraZenecaHealthcare · $240BOncology drug competition
PfizerHealthcare · $160BPharma rivals in oncology and vaccines

Key relationships in depth

Merck & Pfizer

Pfizer and Merck are two of the largest US pharmaceutical companies competing across oncology, vaccines, and infectious disease. Merck's Keytruda (pembrolizumab) is the world's best-selling drug at $25B+ in 2024 annual revenue, while Pfizer's oncology portfolio (Ibrance, Xtandi, Padcev) competes in adjacent cancer indications. Both companies also compete in vaccines: Pfizer's Prevnar franchise versus Merck's vaccines portfolio.

Why it matters: Cancer is the largest and fastest-growing pharmaceutical market, projected to exceed $300B by 2030. Keytruda's dominance across 30+ cancer indications has transformed Merck's revenue profile, while Pfizer's Seagen acquisition (completed 2023 for $43B) bolstered its oncology portfolio with antibody-drug conjugates. The competition for oncologist prescribing habits determines billions in revenue.

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie AstraZeneca Thermo Fisher Novartis Abbott Labs Roche Holding

Embed this on your site

Show Merck's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=MRK" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Merck on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.